Notably, PD-1/PD-L1 antibodies are of lower risk of maculopapular rashes (MPR) compared to CTLA-4 antibodies (Bottlaender et al., 2020; Curry et al., 2017; Minkis et al., 2013). The gene discussed is CTLA4; the disease is maculopapular eruption.